IKT (Inhibikase Pharma) Company Assets

IKT (Inhibikase Therapeutics Inc) - company brandmark

This price evolution chart demonstrates the dynamics of Inhibikase Therapeutics (IKT), whose total assets amount to 126.23. The company operates modern laboratories for developing Parkinson's disease medications equipped with updated hardware. Current revenue is based on partnership agreements and grants, with profits expected from future therapy sales. Meanwhile, molecule synthesis is fully outsourced to external contractors, creating a significant dependency on third-party manufacturers.

inhibikase.com (IKT) Aggregate Company Assets: for the period 07/04/2022 - 11/01/2026

Financial and market metric breakdowns for Inhibikase (IKT)

- stock quotes and analyst forecast:
Share Price inhibikase.com|IKT - Analyst Consensus Forecast
- business market valuation indicators:
Market Value Inhibikase Pharma|IKT - Real Price to Acquire Entire Company
- balance sheet equity data:
Book Value per Share Inhibikase Therapeutics|IKT - Company Book Value|Market Value to Book Value inhibikase.com|IKT - Aggregate Company Assets
- debt and solvency information:
Debt to Capital Inhibikase Therapeutics|IKT - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Inhibikase Pharma|IKT - Company Debts|Debt to Book Value Ratio Inhibikase Pharma|IKT - Company Long-Term Debts|Company Short-Term Loans and Borrowings Inhibikase Therapeutics|Interim Coverage Ratio inhibikase.com
- earnings and market multiples details:
IKT - Net Profit
Basic company analysis:inhibikase.com
Signature product of Inhibikase Therapeutics

The total assets chart for Inhibikase Therapeutics (IKT) reflects the material base of the company, which invests in AI platforms for the automated modeling of Parkinson's disease drugs. This indicator measures the total volume of resources and property controlled by the business, including equity and external liabilities. The value is calculated inversely via return on assets (ROA), allowing for the tracking of the enterprise's physical scale. The metric's dynamics help determine the balance between technological capacity and the risks of a deep capital drawdown.

Direct competitors

Total Business Assets BIIB|NBIX (Neurocrine Biosciences, Inc.) - Company Total Assets|Company Assets Regencell Bioscience Ltd RGC|Cumulative Company Assets AXSM (Axsome Therapeutics Inc)|Company Total Assets ACADIA Corp (ACAD)|Aggregate Company Assets Xenon Pharmaceuticals XENE|Aggregate Asset Value VKTX|SUPN - Aggregate Company Assets|Company Assets Catalyst Pharma|DNLI: Company Total Assets|HRMY - Company Total Asset Base|Aggregate Company Assets Biohaven Ltd.|Total Business Assets AMLX (amylyx.com)|Company Total Assets TRVI|PRAX (Praxis Precision Medicines Inc) - Aggregate Asset Value|Company Total Assets AVXL (Anavex Corp)|Company Total Asset Base CeriBell EEG (CBLL)|Prothena Corporation plc - Company Total Assets|ALEC: Aggregate Company Assets|ANNX: Company Total Assets|OMER - Company Total Asset Base|Aggregate Company Assets Neurogene Corp|Company Total Assets AC Immune Inc|Company Total Assets VYGR|Company Total Assets neumoratx.com (NMRA)|Aggregate Company Assets Scilex SCLX|Company Total Asset Base Tevogen Bio Holdings Inc. (TVGN)|Alpha Cognition Corp - Company Total Assets|Company Assets Cognition Therapeutics Inc.|SAVA (Cassava Sciences, Inc.) - Cumulative Company Assets|Assertio - Aggregate Asset Value|Cumulative Company Assets COYA|VTGN (VistaGen Therapeutics Inc) - Aggregate Business Assets|Company Total Assets OVID|ABOS (Acumen Pharmaceuticals, Inc) - Aggregate Asset Value|Company Total Assets CRVO (CervoMed Inc.)|Alterity Therapeutics Ltd. (ATHE) - Company Assets|CLNN - Aggregate Company Assets|Aggregate Asset Value PEPG (PepGen Inc.)|JUNS: Company Total Assets|Relmada Corp (RLMD) - Company Total Assets|Aggregate Company Assets Annovis Bio, Inc.|Grace Tx - Total Asset Value of Company|Company Total Assets AIFF|KLTO - Company Assets|NeuroSense Therapeutics Ltd. - Cumulative Company Assets|Company Total Assets Reviva Pharmaceuticals, Inc. RVPH|MTVA: Cumulative Company Assets|neuraxis.com - Aggregate Business Assets|HSDT: Company Total Assets|PASG - Company Total Asset Base|NEUP (Neuphoria Therapeutics, Inc.) - Company Total Assets|Cumulative Company Assets Minerva (NERV)|Aggregate Company Assets Athira Pharma, Inc. (ATHA)|Company Total Asset Base addextherapeutics.com|Company Total Assets ALZN (Alzamend Neuro)|Company Total Asset Base Cyclerion Therapeutics Inc. (CYCN)|PTIX - Aggregate Company Assets|KTTA - Company Total Assets|CRGT (cortigent.com) - Cumulative Company Assets|ATXI: Aggregate Business Assets|Aggregate Company Assets BrainStorm Cell Therapeutics|Total Business Assets CARA (Cara Therapeutics Inc.)|Company Total Assets CHRO|ELYM - Company Assets|Intra-Cellular Therapies, Inc. - Cumulative Company Assets|Company Total Assets longboardpharma.com LBPH|MRNS - Aggregate Company Assets|Aggregate Asset Value NKGN (NKGen Biotech Inc)|NeuroBo (NRBO) - Aggregate Company Assets|Company Assets Sage Therapeutics Inc (SAGE)|SNPX (Synaptogenix, Inc.) - Company Total Assets|trevena.com (TRVN) - Company Total Asset Base|Aggregate Company Assets Vigil Neuroscience (VIGL)|anewmeds.com - Total Business Assets|Company Total Assets CERE (Cerevel)